Barber Daniel sold $106K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $4.22 ($0.11M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Oct 16, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 6:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
medium confidence
Mentioned
$AQST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

While the sale reduces the CEO's ownership, the modest size suggests limited market reaction unless accompanied by other news.

02

Market read

A small insider sale; likely negligible impact on AQST's price and the biotech sector.

03

What to watch

Potential upcoming clinical data releases or partnership announcements could outweigh the impact of this small insider sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Aquestive Therapeutics (AQST) is a clinical‑stage biotech developing treatments for respiratory diseases. The filing reflects a routine 10b5‑1 sale by its CEO.

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

CEO Daniel Barber sold 25,000 shares for $105,600 via a 10b5-1 plan, reducing his stake to 627,317 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filings are primary disclosures, but the transaction size is modest for a mid‑cap biotech, limiting material impact.

Market effects

Minimal effect on the broader biotech sector; insider sales are common and rarely shift sector sentiment.

None

None

Counterpoint

The sale could be a routine liquidity event; investors may ignore it if the company's pipeline remains strong.

Key entities

  • Daniel Barber

    President, CEO, and Director of AQST

  • AQST

    Aquestive Therapeutics, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.